Menu
Search
|

Menu

Close
X

Rxi Pharmaceuticals Corp RXII.OQ (NASDAQ Stock Exchange Capital Market)

2.12 USD
-0.03 (-1.40%)
As of 12:00 PM EDT
chart
Previous Close 2.15
Open 2.20
Volume 1,373
3m Avg Volume 60,950
Today’s High 2.20
Today’s Low 2.12
52 Week High 7.68
52 Week Low 1.91
Shares Outstanding (mil) 4.26
Market Capitalization (mil) 9.23
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.898
FY17
-5.671
FY16
-16.178
FY15
-25.967
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.14
Price to Sales (TTM)
vs sector
243.02
8.17
Price to Book (MRQ)
vs sector
10.33
4.30
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.55
LT Debt to Equity (MRQ)
vs sector
0.00
13.12
Return on Investment (TTM)
vs sector
-209.46
13.10
Return on Equity (TTM)
vs sector
-209.46
15.09

EXECUTIVE LEADERSHIP

Robert Bitterman
Independence Chairman of the Board, Since 2013
Salary: --
Bonus: --
Geert Cauwenbergh
President, Chief Executive Officer, acting Chief Financial Officer, Director, Since 2015
Salary: $398,361.00
Bonus: --
Gerrit Dispersyn
Chief Development Officer, Since 2017
Salary: --
Bonus: --
Keith Brownlie
Independent Director, Since 2013
Salary: --
Bonus: --
H. Paul Dorman
Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

257 Simarano Dr Ste 101
MARLBOROUGH   MA   01752-3070

Phone: +1508.7673861

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

SPONSORED STORIES